Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?

First Trust NYSE Arca Biotechnology Index Fund (FBT) and iShares Biotechnology ETF (IBB) offer different approaches to biotech sector exposure. FBT uses a concentrated 30-stock portfolio with higher returns (53.2% one-year, 168% ten-year) but greater risk, while IBB provides broader diversification with 248 holdings and lower fees (0.44% vs 0.55%). FBT has outperformed IBB over the past decade despite higher concentration risk.

07/12/2026, 3:30 PM • The Motley Fool

Many Investors Are Still Treating Gilead Sciences Like a Has-Been HIV Stock. 4 Drug Launches This Year Could Prove Them Wrong.

Gilead Sciences is expanding beyond its core HIV business with four potential drug launches in 2026, including treatments for hepatitis delta virus, multiple myeloma, and breast cancer. Despite strong financials (Q1 revenue up 4% YoY, EPS up 54.8%), the stock has only risen 9% this year. The company's strategic acquisitions and diversified pipeline, combined with no major patent cliffs until 2036 and an attractive 2.39% dividend yield, suggest investors are undervaluing the company's growth potential.

07/12/2026, 9:23 AM • The Motley Fool

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners?

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with 25 concentrated holdings and State Street SPDR S&P Pharmaceuticals ETF (XPH) with 65 diversified holdings. Both charge identical 0.35% expense ratios and offer 0.50% dividend yields, but XPH delivered significantly higher 1-year returns (64.30% vs 33.30%) and lower volatility, making it potentially more suitable for beginners seeking diversification.

07/08/2026, 7:28 AM • The Motley Fool

BBG Advanced Therapies Launches Mobile Leukapheresis Center, in Collaboration with Kite to Bring CAR T-cell Therapies Closer to Patients

BBG Advanced Therapies, a subsidiary of BioBridge Global, has partnered with Kite (a Gilead Company) to deploy a Mobile Leukapheresis Center across Texas. This first-of-its-kind platform brings T-cell collection directly to patients' communities, reducing travel burdens and expanding access to Kite's CAR T-cell therapies for blood cancer treatment. The initiative addresses the gap where only 2 in 10 eligible U.S. patients currently receive these treatments.

07/07/2026, 10:00 AM • GlobeNewswire

Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial

Gilead Sciences and Merck discontinued their Phase 3 KEYNOTE-D46/EVOKE-03 trial evaluating Trodelvy plus Keytruda for lung cancer after the combination failed to reach statistical significance in progression-free survival with low probability of overall survival benefit. However, the companies reported positive Phase 3 results for an investigational once-weekly oral HIV regimen combining islatravir and lenacapavir, which met its primary efficacy endpoints in two studies.

06/09/2026, 1:44 PM • Benzinga

Gilead Advances Liver Disease Ambitions With Encouraging Study Outcome

Gilead Sciences announced positive Phase 3 IDEAL study results for Livdelzi (seladelpar) in treating primary biliary cholangitis (PBC). The drug significantly improved alkaline phosphatase (ALP) normalization compared to placebo in patients with inadequately controlled disease. The company plans to present full data at a medical congress and engage with regulatory authorities. However, GILD shares fell 2.01% on the news.

06/02/2026, 1:47 PM • Benzinga

Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More

RTW Investments, a biotech-focused fund, purchased 11.8 million shares of Tango Therapeutics for approximately $164.37 million in Q1 2026, increasing its stake to roughly 3% of AUM. The purchase comes as TNGX stock has surged 840% over the past year. The investment reflects confidence in Tango's lead candidate vopimetostat and upcoming clinical data for MTAP-deleted cancers, with the company well-funded through 2028.

05/29/2026, 8:21 PM • The Motley Fool

Oorja Bio Launches as a Clinical-Stage Company to Develop Groundbreaking Therapies for Idiopathic Pulmonary Fibrosis (IPF) and Other Fibrotic Diseases

Oorja Bio, a new clinical-stage biopharmaceutical company, announced a $30 million Series A funding round from Westlake BioPartners to develop ORJ-001, a first-in-class peptide therapeutic for idiopathic pulmonary fibrosis (IPF). The company has received FDA IND clearance and plans to initiate Phase 2 clinical trials in 2026. ORJ-001 is designed to restore alveolar epithelial type 2 (AEC2) cell function to promote lung repair and reverse fibrosis, addressing a significant unmet medical need in IPF treatment.

05/19/2026, 3:00 PM • GlobeNewswire

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics announced that its CEO Arthur T. Sands will participate in fireside chats at the RBC Global Healthcare Conference (May 20, 2026) and Jefferies Global Healthcare Conference (June 3, 2026). The company is advancing targeted protein degradation medicines for oncology and autoimmune diseases, with clinical-stage programs including BTK degraders and CBL-B inhibitors, alongside partnerships with Sanofi, Gilead, and Pfizer.

05/13/2026, 7:00 AM • GlobeNewswire

Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference

Assembly Biosciences announced that its Chief Medical Officer, Anuj Gaggar, MD, PhD, will present at the Bank of America Securities 2026 Global Health Care Conference on May 13, 2026. The company also highlighted positive Phase 1b data for its helicase-primase inhibitors ABI-5366 and ABI-1179 for recurrent genital herpes treatment, with additional data selected for oral presentation and late-breaker poster presentation at ESCMID Global 2026.

05/11/2026, 8:00 AM • GlobeNewswire

Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights

Assembly Biosciences reported Q1 2026 financial results with cash reserves of $226.6 million, sufficient to fund operations into 2028. The company completed Phase 1b studies for herpes candidates ABI-5366 and ABI-1179 (licensed to Gilead) and chronic toxicology studies for hepatitis delta virus candidate ABI-6250, with Phase 2 initiation expected in Q4 2026. Net loss was $9.1 million for the quarter.

05/07/2026, 4:00 PM • GlobeNewswire

PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

Over 25 pharmaceutical companies are actively developing 30+ PARP inhibitor drugs in clinical trials, with major players including AstraZeneca, Gilead Sciences, and Nerviano Medical Sciences advancing promising candidates like Saruparib and NMS-293. The pipeline shows robust activity across multiple cancer indications including breast cancer, prostate cancer, and glioblastoma, with approximately 12+ drugs in early to mid-stage development. Recent developments include clinical collaborations and first-in-human trial updates from companies like Acerand Therapeutics and Synnovation Therapeutics.

05/07/2026, 1:00 PM • GlobeNewswire

Rheumatoid Arthritis Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape

DelveInsight's 2026 report reveals a robust rheumatoid arthritis pipeline with 75+ active players developing 80+ drugs across various clinical stages. The report highlights emerging therapies targeting novel pathways beyond traditional TNF inhibition, including JAK inhibitors, BTK inhibitors, and cell-based immunotherapies. Recent developments include positive Phase III results for Lynk Pharmaceuticals' zemprocitinib, FDA Fast Track designation for Artiva Biotherapeutics' AlloNK, and multiple licensing agreements signaling significant innovation in the RA treatment landscape.

04/28/2026, 1:00 PM • GlobeNewswire

Mag 7 Earnings Bonanza, Fed Await Stocks at Record Highs: What to Expect

U.S. stocks hit record highs as the S&P 500 and Nasdaq post their fourth consecutive weekly gains, driven by strong corporate earnings with 84% of S&P 500 companies beating estimates and 15.1% blended earnings growth. The Magnificent Seven tech giants—Microsoft, Alphabet, Amazon, Meta, and Apple—report earnings this week amid geopolitical tensions over U.S.-Iran talks and rising oil prices. The Fed meets Wednesday to decide on interest rates while investors monitor AI infrastructure spending and economic resilience.

04/27/2026, 5:36 AM • Investing

Kailera Therapeutics' Strong IPO Validates "NewCo" Strategy

Kailera Therapeutics, a spinoff of Hengrui Pharma's weight-loss drug portfolio, surged 63% on its Nasdaq debut, validating the 'NewCo' business model where Chinese drugmakers spin off promising pipelines into standalone companies. The IPO raised $625 million, the largest by a Chinese pharma company using this strategy. Hengrui retains a 9.8% stake now valued at ~$300 million and benefits from milestone payments and royalties.

04/23/2026, 12:08 PM • Benzinga